Koh et al. showed that the engineered EVs harboring SIRPα variants (termed SIRPα-exosomes), can be used to competitively bind CD47 on tumor with macrophage, reviving the endocytosis of macrophages on tumor cells, thereby eliminating tumor cell in vitro and in vivo [258]. The gene discussed is SIRPA; the disease is neoplasm.